Efficacy of Istradefylline for the Treatment of ADCY5-Related Disease

Mov Disord Clin Pract. 2020 Sep 7;7(7):852-853. doi: 10.1002/mdc3.13067. eCollection 2020 Oct.

Authors

Ryosuke Miyamoto¹, Toshitaka Kawarai¹, Toshiaki Takeuchi^{1

2}, Yuishin Izumi¹, Satoshi Goto³, Ryuji Kaji^{1

4}

Affiliations

¹ Department of Neurology Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
² Department of Rehabilitation National Hospital Organization Utano Hospital Kyoto Japan.
³ Department of Neurodegenerative Disorders Research Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
⁴ Department of Neurology National Hospital Organization Utano Hospital Kyoto Japan.

Abstract

View Supplementary Video 1 View Supplementary Video 2.

Keywords: ADCY5; adenosine A2A receptor antagonist; dyskinesia; hyperkinetic movement disorder; istradefylline.

© 2020 International Parkinson and Movement Disorder Society.

Publication types

Case Reports